Abdi Ibrahim Pharmaceuticals
https://www.abdiibrahim.com.tr/en/default.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abdi Ibrahim Pharmaceuticals
Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
Alvotech Reels In Abdi Ibrahim For Access To Turkey
In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.
Turkish Health VC Fund Will Invest In US
Turkey will found a venture capital fund to acquire promising pharmaceutical start-ups and to support Turkish researchers in the US. The initiative comes from the industry, with support from the Turkish government. It is expected to gather pace after the elections on June 24.
Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market
The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abdi Ibrahim Ilac Sanayi ve Tic AS
- Abdi Ibrahim Remede Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice